Oncotarget

Research Papers:

Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics

Laura Fernandez del Ama _, Mary Jones, Paul Walker, Anna Chapman, Julia A. Braun, Jasmine Mohr and Adam F. L. Hurlstone

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:40348-40361. https://doi.org/10.18632/oncotarget.9613

Metrics: PDF 833 views  |   HTML 1123 views  |   ?  


Abstract

Laura Fernandez del Ama1, Mary Jones1, Paul Walker1, Anna Chapman1, Julia A. Braun1, Jasmine Mohr1, Adam F. L. Hurlstone1

1Faculty of Life Sciences, The University of Manchester, Manchester, UK

Correspondence to:

Adam F. L. Hurlstone, email: adam.hurlstone@manchester.ac.uk

Keywords: melanoma, zebrafish, MEK, PI3K, mTOR

Received: January 04, 2016    Accepted: May 04, 2016    Published: May 26, 2016

ABSTRACT

Phenotype-guided re-profiling of approved drug molecules presents an accelerated route to developing anticancer therapeutics by bypassing the target-identification bottleneck of target-based approaches and by sampling drugs already in the clinic. Further, combinations incorporating targeted therapies can be screened for both efficacy and toxicity. Previously we have developed an oncogenic-RAS-driven zebrafish melanoma model that we now describe display melanocyte hyperplasia while still embryos. Having devised a rapid method for quantifying melanocyte burden, we show that this phenotype can be chemically suppressed by incubating V12RAS transgenic embryos with potent and selective small molecule inhibitors of either MEK or PI3K/mTOR. Moreover, we demonstrate that combining MEK inhibitors (MEKi) with dual PI3K/mTOR inhibitors (PI3K/mTORi) resulted in a super-additive suppression of melanocyte hyperplasia. The robustness and simplicity of our novel screening assay inspired us to perform a modest screen of FDA approved compounds for their ability to potentiate MEKi PD184352 or PI3K/mTORi NVPBEZ235 suppression of V12RAS-driven melanocyte hyperplasia. Through this route, we confirmed Rapamycin as a compound that could synergize with MEKi and even more so with PI3K/mTORi to suppress melanoma development, including suppressing the growth of cultured human melanoma cells. Further, we discovered two additional compounds—Disulfiram and Tanshinone—that also co-operate with MEKi to suppress the growth of transformed zebrafish melanocytes and showed activity toward cultured human melanoma cells. In conclusion, we provide proof-of-concept that our phenotype-guided screen could be used to identify compounds that affect melanoma development and prompt further evaluation of Disulfiram and Tanshinone as possible partners for combination therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9613